Trials / Completed
CompletedNCT00180167
Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC
Therapy of AML in Patients Older Than 60 Years: Randomized Comparison of a Double Induction With Daunorubicin and AraC (as Continuous Infusion) With a Double Induction With Mitoxantrone and Intermittent, Medium High Dose AraC
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 492 (actual)
- Sponsor
- Technische Universität Dresden · Academic / Other
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
Single Arm-Studies suggest improved remission and survival rates for a Protocol with Mitoxantron 10mg/m2 for 3 days combined with AraC 1g/m2 bid on days 1+3+5+7 compared to a conventional DA 7+3 protocol (45mg/m2 Daunorubicin).
Detailed description
Randomized comparison of the two protocols.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | randomization between two established Chemotherapies |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2005-09-16
- Last updated
- 2010-08-20
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00180167. Inclusion in this directory is not an endorsement.